PCSK9 was lowered by as much as 84 percent in the cohorts that received higher infusion rates of the treatment.
The current go-to treatments for high cholesterol, such as statins and PCSK9 inhibitors, require strict adherence and can have negative side effects.
Before reaching consumers, the therapy will need to be studied for up to 15 years according to FDA regulations.
[
add
]
[
|
|
...
]